Key Highlights

  • Acadia Pharmaceuticals (NASDAQ:ACAD) declined 22.28% on November 9, 2026, reaching a 52-week low near USD 18 after it released third-quarter figures.
  • Revenue of around USD 342 million topped the roughly USD 332 million consensus, while adjusted Earnings Per Share of USD 0.31 beat the USD 0.20 forecast.
  • Attention stayed on remlifanserin, a candidate for Alzheimer's disease psychosis that narrowly fell short of its main goal in a Phase 2 trial that was reported in September.
  • Full-year 2026 Revenue guidance was tightened to USD 1.265 billion through USD 1.295 billion, while DAYBUE sales climbed 39% and NUPLAZID rose roughly 12% during the quarter.

Results Beat Expectations Yet Shares Retreated

The commercial performance at Acadia Pharmaceuticals (NASDAQ:ACAD) was sound during the quarter. DAYBUE, the Rett syndrome therapy, produced net sales near USD 140 million, a 39% increase on the prior year, and NUPLAZID, used for Parkinson's disease psychosis, brought in about USD 202 million, up roughly 12% on an adjusted footing. Revenue of about USD 342 million exceeded forecasts, and adjusted earnings per share of USD 0.31 were comfortably ahead of estimates. Management narrowed the full-year revenue corridor to USD 1.265 billion through USD 1.295 billion. Even so, the stock slid 22.28% to its weakest level in twelve months, indicating that investors are pricing the company on what comes next in its pipeline rather than on current medicines. NUPLAZID will eventually face generic rivals, which makes fresh growth engines essential to long-run value and to keeping revenue rising past the end of the decade.

Remlifanserin Trial Data and Its Market Weight

Remlifanserin represents the company's main wager on a far larger opportunity. Alzheimer's disease psychosis, marked by hallucinations and delusions, affects a sizeable and expanding group of patients who have few approved options. In the Phase 2 portion of the RADIANT study, disclosed in September 2026, 326 patients were randomized across 60 mg, 30 mg and placebo arms for six weeks. The 60 mg arm reduced symptoms by 12.6 points, compared with 10.4 points for placebo. That gap narrowly missed statistical significance, with a p-value of 0.0603, although a major secondary gauge of overall severity reached nominal significance. The company discontinued the 30 mg group and is advancing 60 mg into Phase 3. The sharp decline on November 9, 2026 suggests investors are not yet persuaded that the planned Phase 3 design can produce a clear win, particularly given the strong placebo responses common in psychiatric studies involving older patients.

Safety Profile, Pending Data and Investor Watch List

The company's update did not identify a specific trigger for the size of the November 9 decline, which adds uncertainty. Shares had already lost more than 20% during 2026 before the drop. The chief dangers facing Acadia Pharmaceuticals (NASDAQ:ACAD) are a Phase 3 setback for remlifanserin, slower growth at DAYBUE and future generic pressure on NUPLAZID. Safety data so far look clean, with no new signals, few cases of somnolence and nausea and no QT prolongation. Investors will focus on additional remlifanserin results at a major Alzheimer's meeting in Boston from November 16 to 19, 2026, the Phase 3 protocol details and ongoing DAYBUE expansion, including a new formulation. A Phase 2 trial in Lewy body dementia is expected to report in early 2028.

Where Things Stand

Acadia dropped 22.28% to a 52-week low on November 9, 2026, despite third-quarter revenue and earnings above expectations, as doubts about the remlifanserin path in Alzheimer's disease psychosis dominated trading. DAYBUE and NUPLAZID are still growing. Fresh fresh remlifanserin data at the November 16 to 19 meeting and the Phase 3 design are the next catalysts.